Phase 2 Leucine-Restricted Diet, Gastric Cancer Study

NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07537361) investigating the safety and efficacy of a leucine-restricted diet in combination with neoadjuvant chemotherapy and immunotherapy for gastric cancer patients. The study's conditions include gastric cancer and the dietary intervention, with the primary focus on evaluating patient safety, tolerability, and immune response within the tumor microenvironment.

For affected parties including clinical investigators, oncology research institutions, and pharmaceutical companies involved in immuno-oncology drug development, this trial registration signals ongoing interest in metabolic and dietary approaches as complementary cancer therapies. The trial does not create immediate compliance obligations but may inform future dietary intervention protocols and combination treatment strategies in gastric cancer care.